Plain-English translation of NCT06701357 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing chidamide combined with standard chemotherapy (called R-CHOP) for people newly diagnosed with diffuse large B-cell lymphoma that has two specific genetic markers called MYC and BCL2. The study will give you one round of standard chemotherapy, then add chidamide or other targeted drugs based on your specific genetic profile for the remaining five rounds. If the treatment works well, you'll continue taking chidamide for up to two years to help prevent the cancer from coming back.
This aggressive form of lymphoma is difficult to treat and has a poor outlook with standard chemotherapy alone. Researchers believe that adding this medication to standard treatment may help more patients achieve long-term remission and improve survival.
You likely qualify if…
You likely don't qualify if…
You will receive six rounds of treatment over several months. The first round is standard chemotherapy alone. For the remaining five rounds, you will receive standard chemotherapy plus one of three targeted medications (chidamide, a PD1 inhibitor, orelabrutinib, or decitabine), depending on your specific genetic profile. The research team will evaluate how well the treatment is working after every round and do a comprehensive assessment after three rounds. If the treatment works well, you will then take chidamide as a maintenance therapy for up to two years unless you experience intolerable side effects or the cancer progresses.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Ruijin Hospital
Enrollment target
~49 participants
Started
December 2024
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Li Wang
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.